New drug trial aims for major weight loss in obesity
NCT ID NCT07220642
Summary
This study is testing whether a new investigational medicine called cagrilintide helps people with overweight or obesity lose weight and improve their health. About 300 adults will receive either cagrilintide or a placebo (dummy treatment) by random chance for about 18 months. Researchers will measure how much weight participants lose, track side effects, and see if the drug improves quality of life and other health markers like blood pressure and cholesterol.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Bologna_ Policlinico S.Orsola Malpighi
Bologna, 40138, Italy
-
AOUP Giaccone Palermo
Palermo, Sicily, 90127, Italy
-
Brunel Medical Practice
Torquay, Devon, TQ1 4QX, United Kingdom
-
CEDIC Centro de Investigación Clínica
CABA, C1060ABA, Argentina
-
CIPREC Pueyrredon
Buenos Aires, C1119ACN, Argentina
-
Care Clinic Sp. z o. o.
Katowice, 40-568, Poland
-
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec
Saint-Herblain, 44800, France
-
Centre de Recherche Clinique Portes Du Sud
Vénissieux, 69200, France
-
Centricity Research Mirabel
Mirabel, Quebec, J7J 2K8, Canada
-
Centricity Research Oshawa
Oshawa, Ontario, L1J 2K9, Canada
-
Centricity Research Toronto
Toronto, Ontario, M4G 3E8, Canada
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
Drammen sykehus - Vestre Viken HF
Drammen, 3004, Norway
-
Florida Inst For Clin Res LLC
Orlando, Florida, 32825, United States
-
Fondazione Policlinico Universitario Agostino Gemelli IRCS
Rome, RM, 00168, Italy
-
G.A. Research Associates Ltd.
Moncton, New Brunswick, E1G 1A7, Canada
-
Hamilton Medical Rsrch Grp
Hamilton, Ontario, L8L 5G4, Canada
-
Haukeland Universitetssykehus
Bergen, 5021, Norway
-
Hunter Diabetes Centre
Merewether, New South Wales, 2291, Australia
-
IRCCS Ospedale San Raffaele Milano
Milan, 20132, Italy
-
InnoDiab Forschung GmbH
Essen, 45136, Germany
-
Midwest Inst For Clin Res
Indianapolis, Indiana, 46260, United States
-
Milestone Research
London, Ontario, N5W 6A2, Canada
-
NBR Polska Tomasz Klodawski
Warsaw, 00-710, Poland
-
North Coast Medical Ltd
Newquay, Cornwall, TR7 1RU, United Kingdom
-
Nova Scotia Hlth Halifax
Halifax, Nova Scotia, B3H 1V7, Canada
-
Oak Tree Surgery
Liskeard, Cornwall, PL14 3XA, United Kingdom
-
Osteo-Medic s.c. A. Racewicz, J. Supronik
Bialystok, 15-351, Poland
-
Oviedo Medical Research, LLC
Oviedo, Florida, 32765, United States
-
PharmQuest Life Sciences LLC
Greensboro, North Carolina, 27408, United States
-
RED-Institut für medizinische Forschung und Fortbildung GmbH
Oldenburg in Holstein, 23758, Germany
-
Selma Medical Associates
Winchester, Virginia, 22601-3834, United States
-
St. Olavs Hospital HF
Trondheim, NO-7030, Norway
-
StudyMetrix Research LLC
City of Saint Peters, Missouri, 63303, United States
-
Sydney Cardiometabolic Centre
Liverpool, New South Wales, 2170, Australia
-
Terpa Sp. z o.o. Sp. k.
Lublin, 20-333, Poland
-
Univ of Colorado at Denver
Aurora, Colorado, 80045, United States
-
Walgreens - Store 11760
Oak Park, Illinois, 60302, United States
-
Wendisch - Dahl Hamburg - DZHW
Hamburg, 22607, Germany
-
Wharton Med Clin Trials
Hamilton, Ontario, L8L 5G8, Canada
Conditions
Explore the condition pages connected to this study.